Last reviewed · How we verify
Capecitabine, Cyclophosphamide
Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Cyclophosphamide is an alkylating agent that attaches an alkyl group to the DNA of cancer cells, thereby interfering with their replication.
Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Cyclophosphamide is an alkylating agent that attaches an alkyl group to the DNA of cancer cells, thereby interfering with their replication. Used for Metastatic breast cancer, Advanced colorectal cancer.
At a glance
| Generic name | Capecitabine, Cyclophosphamide |
|---|---|
| Sponsor | Vastra Gotaland Region |
| Drug class | Antineoplastic |
| Target | Thymidylate synthase, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Capecitabine's mechanism of action is similar to that of 5-fluorouracil, a thymidylate synthase inhibitor. Cyclophosphamide's mechanism of action involves the formation of DNA cross-links, which prevent DNA replication and transcription. This leads to cell death, particularly in rapidly dividing cancer cells.
Approved indications
- Metastatic breast cancer
- Advanced colorectal cancer
Common side effects
- Hand-foot syndrome
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Neutropenia
- Anemia
- Thrombocytopenia
- Leukopenia
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors (PHASE1, PHASE2)
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) (PHASE2)
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer (PHASE2)
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (PHASE3)
- BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer (PHASE2)
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine, Cyclophosphamide CI brief — competitive landscape report
- Capecitabine, Cyclophosphamide updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI